Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287223 | 1.00 | ALDH1A1 (0.36) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL287224 | 1.00 | ALDH1A1 (0.36) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL27851967 | 0.79 | POLB (0.37) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL27868928 | 0.78 | POLB (0.39) | ALDH1A1POLBCYP2C19L3MBTL1HTT | |
| SCHEMBL287072 | 0.76 | CYP2C19 (0.39) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL287071 | 0.76 | CYP2C19 (0.39) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL287232 | 0.74 | MEN1 (0.45) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL287231 | 0.74 | MEN1 (0.45) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL287233 | 0.74 | MEN1 (0.45) | ALDH1A1POLBCYP2C19L3MBTL1GAA | |
| SCHEMBL287070 | 0.67 | MEN1 (0.42) | ALDH1A1POLBCYP2C19L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461160-B2 | Dihydropyrimidinones | HOFFMANN-LA ROCHE, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2427437-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | ALDH1A1 563/4885POLB 3301/4885CYP2C19 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.